13F Holdings
中文EN

IDYA IDEAYA Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1676725 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-70.1%
TTM net income YoY-143.0%
TTM EPS YoY-71.4%
Revenue 3-yr CAGR-37.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,671.1%
Net margin-3,921.1%
FCF margin-3,592.0%
EBITDA margin-4,637.0%

Returns

ROE-32.7%
ROA-31.0%
ROIC (approx.)-35.9%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets5.8%
Debt / equity0.00x
Current ratio14.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-3.0%
Payout ratio—
Capex / revenue55.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$218.71M$7.00M$23.39M$50.93M$27.94M
R&D expense$314.70M$294.67M$129.51M$89.54M$58.16M
SG&A expense$63.32M$39.30M$28.31M$23.90M$20.05M
Operating income-$159.31M-$326.98M-$134.43M-$62.50M-$50.27M
Income tax$0$0$0$0$0
Net income-$113.70M-$274.48M-$112.96M-$58.66M-$49.76M
EBITDA-$156.61M-$324.59M-$131.95M-$60.40M-$48.54M
EPS (basic)-1.28-3.36-1.96-1.42-1.41
EPS (diluted)-1.28-3.36-1.96-1.42-1.41
Weighted avg. shares (diluted)88.49M81.68M57.52M41.44M35.25M
Balance sheet
Cash & equivalents$112.83M$85.18M$157.02M$68.74M$92.15M
Short-term investments$526.56M$591.94M$368.10M$296.20M$154.72M
Receivables—$3,000$18,000$211,000$1.10M
Current assets$666.73M$689.71M$532.63M$370.45M$251.00M
PP&E, net$8.22M$8.97M$6.16M$6.51M$4.76M
Total assets$1.11B$1.12B$649.32M$387.97M$381.35M
Current liabilities$58.81M$46.07M$27.10M$31.72M$45.16M
Total liabilities$86.39M$64.94M$28.23M$38.51M$79.83M
Shareholders' equity$1.02B$1.06B$621.09M$349.45M$301.51M
Shares outstanding87.80M86.50M65.04M48.19M38.53M
Cash flow statement
Operating cash flow-$71.10M-$247.58M-$115.22M-$87.17M-$55.78M
Capital expenditure$2.37M$3.86M$2.37M$3.44M$2.64M
Free cash flow-$73.47M-$251.44M-$117.59M-$90.62M-$58.42M
Investing cash flow$69.98M-$502.56M-$158.46M-$33.40M-$69.67M
Financing cash flow$29.78M$677.55M$362.72M$97.17M$145.45M
Depreciation & amortization$2.70M$2.39M$2.48M$2.10M$1.73M
Stock-based compensation$46.12M$34.75M$18.49M$11.63M$8.24M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.